^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QLS31904

    i
    Associations
    News

    Trials

    Company:
    Qilu Pharma
    Drug class:
    CD3 agonist, DLL3 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors (QLS31904-101) (NCT05461287)
    Phase 1
    Qilu Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/10/2022
    Initiation :
    09/30/2022
    Primary completion :
    09/25/2024
    Completion :
    05/25/2025
    DLL3
    |
    DLL3 expression
    |
    QLS31904